Cidara Therapeutics (CDTX) Net Income towards Common Stockholders: 2017-2025
Historic Net Income towards Common Stockholders for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to -$83.2 million.
- Cidara Therapeutics' Net Income towards Common Stockholders fell 18396.22% to -$83.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$132.4 million, marking a year-over-year decrease of 4615.68%. This contributed to the annual value of $464,000 for FY2024, which is 78.41% down from last year.
- Latest data reveals that Cidara Therapeutics reported Net Income towards Common Stockholders of -$83.2 million as of Q3 2025, which was down 223.64% from -$25.7 million recorded in Q2 2025.
- In the past 5 years, Cidara Therapeutics' Net Income towards Common Stockholders ranged from a high of $11.9 million in Q3 2022 and a low of -$83.2 million during Q3 2025.
- Its 3-year average for Net Income towards Common Stockholders is -$11.9 million, with a median of -$450,000 in 2024.
- In the last 5 years, Cidara Therapeutics' Net Income towards Common Stockholders surged by 175.65% in 2023 and then slumped by 18,396.22% in 2025.
- Cidara Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$16.8 million in 2021, then climbed by 20.39% to -$13.4 million in 2022, then soared by 137.14% to $5.0 million in 2023, then crashed by 98.75% to $62,000 in 2024, then plummeted by 18,396.22% to -$83.2 million in 2025.
- Its last three reported values are -$83.2 million in Q3 2025, -$25.7 million for Q2 2025, and -$23.5 million during Q1 2025.